Business
Theralase Demonstrates Anti-Cancer Technology Prevents Recurrence of Bladder Cancer at 180 Days Post-Treatment
Theralase Demonstrates Anti-Cancer Technology Prevents Recurrence of Bladder Canc...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Demonstrates Anti-Cancer Technology Prevents Recurrence of Bladder Cancer at 180 Days Post-Treatment \n\t\t\tbody { font-size: 11pt;\n\t\t\t}\n\n\t\t\t.nr-sub-head ul,\n\t\t\t.nr-body ul {\n\t\t\t\tlist-style-type: disc !important;\n\t\t\t\tmargin-left: 2em !important;\n\t\t\t}\n\n\t\t\t.nr-sub-head ol,\n\t\t\t.nr-body ol {\n\t\t\t\tmargin-left: 2em !important;\n\t\t\t}\n\n\t\t\t.nr-body p, .nr-body {margin-bottom: 0px !important;\n\t\t\t\t\tmargin-top: 0px !important;\n\t\t\t\t\t-webkit-margin-before: 0px !important;\n\t\t\t\t\t-webkit-margin-after: 0px !important;\n\t\t\t\t\tfont-family: Arial !important;\n\t\t\t\t\tfont-size: 11pt !important;\n\t\t\t }\n\n\t\t\ttbody {\n\t\t\t\tborder-top: 0;\n\t\t\t}\n\n\t\t\t H1 {font-weight: bold;\n\t\t\t\tfont-size: 16pt;\n\t\t\t }\n\n\t\t\t H2 {font-weight: bold;\n\t\t\t\tfont-size: 12pt;\n\t\t\t }\n\n\t\t\t H3 {font-weight: bold;\n\t\t\t\tfont-size: 11pt;\n\t\t\t }\n\n\n\t\t\t H1.nr-head {\n\t\t\t \t\tfont-family: Trebuchet MS !important;\n\t\t\t \t\tfont-size: 16pt !important;\n\t\t\t \t\tcolor: #3D86C6 !important;\n\t\t\t \t\tfont-weight:bold !important;\n\t\t\t \t\ttext-align:center !important;\n\n\t\t\t }\n\n\t\t\t H2.nr-sub-head {font-weight: bold !important;\n\t\t\t \t\tdisplay: block !important;\n\t\t\t \t\ttext-align: start !important;\n\t\t\t \t\tfont-family: Arial !important;\n\t\t\t\t\tfont-size: 12pt !important;\n\t\t\t }\n\n\t\t\t .nr-body a { font-size: 11pt !important;\n\t\t\t }\n\n\t\t\t TABLE { width: auto!important;\n\t\t\t }\n\n\t\t Theralase Demonstrates Anti-Cancer Technology Prevents Recurrence of Bladder Cancer at 180 Days Post-Treatment\n Patient Five Demonstrates No Clinical Evidence of NMIBC at 180 Day Cystoscopy Analysis\n Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers has provided an update on patient five, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”).\n\n \n\nThe Study’s purpose was to e...